| scholarly article | Q13442814 |
| P50 | author | Sabine Steffens | Q63357516 |
| Nikolai G. Rainov | Q70270544 | ||
| P2093 | author name string | Fischer U | |
| Schroten H | |||
| Burdach S | |||
| Kramm CM | |||
| Frank S | |||
| Horneff G | |||
| Banning U | |||
| Niehues T | |||
| Korholz D | |||
| P433 | issue | 1 | |
| P921 | main subject | pediatric ependymoma | Q7159224 |
| patient | Q181600 | ||
| Herpes simplex virus type 1 | Q655331 | ||
| ependymoma | Q1346753 | ||
| teenager | Q1492760 | ||
| P304 | page(s) | 6-9 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Neuropediatrics | Q15763258 |
| P1476 | title | Systemic activation of the immune system during ganciclovir treatment following intratumoral herpes simplex virus type 1 thymidine kinase gene transfer in an adolescent ependymoma patient | |
| P478 | volume | 33 |
| Q36367428 | Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas |
| Q35610300 | Clinical trials with retrovirus mediated gene therapy--what have we learned? |
| Q45883534 | Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results |
| Q35118933 | Gene therapy and targeted toxins for glioma |
| Q57006162 | Gene therapy and targeted toxins for glioma |
| Q39678222 | Integration of adenovirus thymidine kinase suicide-gene therapy with surgery and radiation therapy for malignant glioma |
| Q37502749 | Management strategies for recurrent ependymoma in the paediatric population |
| Q24792836 | Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy) |
| Q30440953 | Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University. |
| Q35216664 | Recombinant retrovirus vectors for treatment of malignant brain tumors |
| Q58484770 | The impact of inflationary cytomegalovirus-specific memory T cells on anti-tumour immune responses in patients with cancer |
Search more.